Epi-on, a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, demonstrated significant improvement in maximum corneal curvature at 6 months from baseline, according to a Glaukos press release.
Epi-on is designed to reduce procedure time, improve comfort and shorten recovery time. It uses a proprietary novel drug formulation to penetrate the epithelial layer of the cornea to enhance cross-linking. According to the release, Epi-on has a stronger UVA irradiation protocol and delivers increased levels of supplemental oxygen.
A phase 3 pivotal trial was designed to
Uncategorized